Nastech Makes Further Job Cuts In Second-Round Restructuring
This article was originally published in The Pink Sheet Daily
Executive Summary
Eliminations will reduce cash burn to focus on near-term business initiatives like finding a new partner for teriparatide nasal spray.
You may also be interested in...
Renamed Nastech Turns To RNAi
Company to divest intranasal program rather than spin out.
Renamed Nastech Turns To RNAi
Company to divest intranasal program rather than spin out.
Nastech Finalizes Plans For RNAi Subsidiary To Focus On Phase II Inhaled Drug Programs
Restructuring includes spinning out RNAi business, reducing 30 percent of work force to conserve cash.